Determination of MICs of Aminocandin for Candida spp. and Filamentous Fungi
Authors:
- 1 December 2006
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 44 (12) , 4342-4344
Abstract
Candida and As pergillus spp., as well as other filamentous molds, have increasingly been reported as the causes of severe invasive fungal infections. We evaluated the new echinocandin aminocandin (AMN) for its antifungal activities against a range of fungal pathogens by determination of the MICs for the organisms. The MICs of the comparator drugs amphotericin B, caspofungin, micafungin, and voriconazole were also determined. The MICs of AMN for 25 strains each of non- Candida albicans Candida spp. (including Candida parapsilosis , Candida krusei , Candida guilliermondii , and Candida tropicalis ), Aspergillus fumigatus , Scedosporium spp., Fusarium spp., and zygomycetes (including Absidia , Mucor , and Rhizopus spp.) were determined by using the Clinical and Laboratory Standards Institute M27-A2 and M38-A methodologies for yeasts and filamentous molds, respectively. The MIC ranges of AMN for all yeasts were similar (0.03 to 4.0 μg/ml), while the MIC ranges of AMN for filamentous fungi were species specific. AMN demonstrated potent antifungal activity against A. fumigatus , limited activity against Scedosporium spp., and no activity against zygomycetes or Fusarium spp. Our data showed that AMN demonstrated potent antifungal activities against all of the yeasts and Aspergillus isolates tested, suggesting that AMN could be an important addition to our arsenal of antifungals for the treatment of invasive fungal disease.Keywords
This publication has 17 references indexed in Scilit:
- Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasisInternational Journal of Antimicrobial Agents, 2006
- Fungal InfectionsProceedings of the American Thoracic Society, 2006
- Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal TherapyJournal of Clinical Microbiology, 2006
- Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infectionsJournal of Infection, 2006
- Changing patterns and trends in systemic fungal infectionsJournal of Antimicrobial Chemotherapy, 2005
- Echinocandins: role in antifungal therapy, 2005Expert Opinion on Pharmacotherapy, 2005
- Letter from the EditorsInfectious Diseases in Clinical Practice, 2005
- Fusarium Infections in Critically Ill PatientsSeminars in Respiratory and Critical Care Medicine, 2004
- Echinocandin antifungal drugsThe Lancet, 2003
- In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant IsolatesAntimicrobial Agents and Chemotherapy, 2003